{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:09:15Z","timestamp":1759018155465,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.jinf.2011.12.017","type":"journal-article","created":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T20:14:51Z","timestamp":1325189691000},"page":"417-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity"],"prefix":"10.1016","volume":"64","author":[{"given":"Ildefonso","family":"Pulido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kawthar","family":"Machmach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda C.","family":"Romero-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Genebat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Mendez-Lagares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezequiel","family":"Ruiz-Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2011.12.017_bib1","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1097\/QAD.0b013e328332d32d","article-title":"When and how to use maraviroc in HIV-infected patients","volume":"23","author":"Soriano","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2011.12.017_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2011.12.017_bib3","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2011.12.017_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","article-title":"Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection","volume":"201","author":"Cooper","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2011.12.017_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/QAI.0b013e3181c5c83b","article-title":"CD4+ T-Cell restoration after 48 Weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2","volume":"54","author":"Asmuth","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2011.12.017_bib6","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/598965","article-title":"A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1","volume":"199","author":"Saag","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2011.12.017_bib7","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1097\/QAD.0b013e32832e71cd","article-title":"CCR5 antagonism in HIV infection: ways, effects, and side effects","volume":"23","author":"Corbeau","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2011.12.017_bib8","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm1319","article-title":"Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1","volume":"11","author":"F\u00e4tkenheuer","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.jinf.2011.12.017_bib9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jac\/dkp293","article-title":"Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients","volume":"64","author":"Genebat","year":"2009","journal-title":"J Antimicrob Chemoter"},{"key":"10.1016\/j.jinf.2011.12.017_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.imlet.2009.10.001","article-title":"CD27 and CCR7 expression on naive T cells, are both necessary?","volume":"127","author":"Ferrando-Martinez","year":"2010","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jinf.2011.12.017_bib11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/JVI.01079-06","article-title":"Inhibition of human immunodeficiency virus envelope glycoprotein-mediated single cell lysis by low-molecular-weight antagonists of viral entry","volume":"81","author":"Madani","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jinf.2011.12.017_bib12","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1097\/QAD.0b013e32832f3c65","article-title":"Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery","volume":"23","author":"Stepanyuk","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2011.12.017_bib13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/QAD.0b013e3283474187","article-title":"Maraviroc intensification for suboptimal CD4+ T cell response in a perinatally HIV-infected adolescent","volume":"25","author":"Espiau","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2011.12.017_bib14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJM200010053431407","article-title":"T-cell function and migration. Two sides of the same coin","volume":"343","author":"von Andrian","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2011.12.017_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1089\/aid.2009.0278","article-title":"A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection","volume":"26","author":"Pett","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jinf.2011.12.017_bib16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/QAD.0b013e3280f00f9f","article-title":"Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults","volume":"21","author":"Sch\u00fcrmann","year":"2007","journal-title":"AIDS"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445311006219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445311006219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:16:41Z","timestamp":1759007801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445311006219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0163445311006219"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2011.12.017","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2011.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}